Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.
作者信息
Chiu Nicholas, Aggarwal Rahul, Bhatt Deepak L
机构信息
Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School Boston MA.
Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston MA.
出版信息
J Am Heart Assoc. 2022 Aug 16;11(16):e026297. doi: 10.1161/JAHA.122.026297. Epub 2022 Aug 5.
Abstract
摘要
相似文献
1
Generalizability of the SURPASS-2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control.SURPASS-2试验的可推广性以及替尔泊肽对美国糖尿病和肥胖控制的影响。
J Am Heart Assoc. 2022 Aug 16;11(16):e026297. doi: 10.1161/JAHA.122.026297. Epub 2022 Aug 5.
2
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.在 2 型糖尿病患者中，体重变化与替西帕肽治疗的血糖控制之间的关系：SURPASS 临床试验计划的事后评估。
Diabetes Obes Metab. 2023 Sep;25(9):2553-2560. doi: 10.1111/dom.15140. Epub 2023 May 29.
3
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.在SURPASS-1单药治疗试验中，停用替尔泊肽4周后对糖化血红蛋白和体重变化的影响。
Diabetes Obes Metab. 2024 Jan;26(1):396-399. doi: 10.1111/dom.15325. Epub 2023 Oct 25.
4
Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.替尔泊肽用于治疗糖尿病和肥胖症：开启非酒精性脂肪性肝炎治疗的新窗口。
Curr Med Chem. 2023;30(22):2476-2479. doi: 10.2174/0929867330666230106103202.
5
[Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes].聚焦替尔泊肽，一种用于2型糖尿病的双靶点单分子GIP - GLP - 1受体激动剂
Rev Med Suisse. 2022 Aug 24;18(792):1539-1544. doi: 10.53738/REVMED.2022.18.792.1539.
6
Tirzepatide: A promising treatment for obesity?替尔泊肽：肥胖症的治疗新希望？
JAAPA. 2023 Nov 1;36(11):9-10. doi: 10.1097/01.JAA.0000979484.51712.33.
7
Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes.退出访谈：评估替西帕肽治疗 2 型糖尿病临床试验中患者体验
Patient. 2022 May;15(3):367-377. doi: 10.1007/s40271-022-00578-8. Epub 2022 May 6.
8
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.替尔泊肽：一种葡萄糖依赖性胰岛素促泌多肽（GIP）和胰高血糖素样肽-1（GLP-1）双重激动剂，正在开发用于治疗 2 型糖尿病。
Expert Rev Endocrinol Metab. 2020 Nov;15(6):379-394. doi: 10.1080/17446651.2020.1830759. Epub 2020 Oct 8.
9
Tirzepatide Trial Demonstrates Substantial Weight Loss.替尔泊肽试验显示出显著的体重减轻。
JAMA. 2022 Jul 26;328(4):322. doi: 10.1001/jama.2022.11895.
10
Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity.替尔泊肽（Mounjaro）——一种用于治疗肥胖症的新型药物治疗剂。
J Pak Med Assoc. 2023 May;73(5):1171. doi: 10.47391/JPMA.7685.
引用本文的文献
1
Enhancing glycaemic control with impetus on weight management: Observing for early worsening of diabetic retinopathy.加强血糖控制并注重体重管理：观察糖尿病视网膜病变早期病情恶化情况。
Eye (Lond). 2024 Jul;38(10):1787-1788. doi: 10.1038/s41433-024-02980-y. Epub 2024 Feb 10.
2
Tirzepatide: A Systematic Update.替尔泊肽：系统更新。
Int J Mol Sci. 2022 Nov 23;23(23):14631. doi: 10.3390/ijms232314631.
本文引用的文献
1
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.替尔泊肽与司美格鲁肽每周一次治疗 2 型糖尿病患者的疗效比较。
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
2
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.司美格鲁肽 2·4 毫克每周一次治疗超重或肥胖、以及 2 型糖尿病成人患者（STEP 2）：一项随机、双盲、双模拟、安慰剂对照、3 期临床试验。
Lancet. 2021 Mar 13;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0. Epub 2021 Mar 2.
3
9. Pharmacologic Approaches to Glycemic Treatment: .9. 血糖治疗的药物学方法： 。
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009.
Zotero 插件